(2025)
Safety, bactericidal activity, and pharmacokinetics of the antituberculosis drug candidate BTZ-043 in South Africa (PanACEA-BTZ-043–02): an open-label, dose-expansion, randomised, controlled, phase 1b/2a trial.
Lancet Microbe 6(2),
100952.
Publikationen
(2025)
Convergent evolution of a fungal effector enabling phagosome membrane penetration.
bioRxiv
[Preprint]
(2025)
Pilot scale production of a F420 precursor under microaerobic conditions.
Biotechnol J 20(3),
e70002.
(2025)
The clinical-stage drug BTZ-043 accumulates in murine tuberculosis lesions and efficiently acts against Mycobacterium tuberculosis.
Nat Commun 16(1),
826.
(2024)
In vitro antibacterial activity of microbial natural products against bacterial pathogens of veterinary and zoonotic relevance.
Antibiotics (Basel) 13(2),
135.
(2024)
Manipulation of host phagocytosis by fungal pathogens and therapeutic opportunities.
Nat Microbiol 9(9),
2216-2231.
(Review)
(2024)
Modulation of the Meisenheimer complex metabolism of nitro-benzothiazinones by targeted C-6 substitution.
Commun Chem 7(1),
153.
(2024)
Deazaflavin metabolite produced by endosymbiotic bacteria controls fungal host reproduction.
ISME J 18(1),
wrae074.
(2024)
Replacement of the essential nitro group by electrophilic warheads towards nitro-free antimycobacterial benzothiazinones.
Eur J Med Chem 279,
116849.
(2023)
Prenylated isoflavanones with antimicrobial potential from the root bark of Dalbergia melanoxylon.
Metabolites 13(6),
678.